Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement Access content directly
Journal Articles Ophthalmology and Therapy Year : 2022

Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry

Abstract

Introduction: Phase III clinical trials of dexamethasone intravitreal implant for diabetic macular oedema (DMO) have reported significant improvements in visual acuity (VA). Studies evaluating the treatment of DMO in routine clinical practice provide data to identify areas that need improvement. This study evaluated 12-month treatment outcomes of dexamethasone implant for DMO in routine clinical practice. Methods: Retrospective data analysis of eyes that started dexamethasone implant for DMO from 1 June 2013 to 30 April 2019 in routine clinical practice tracked in the Fight Retinal Blindness! Registry.
Fichier principal
Vignette du fichier
bhandari_2022_vol18_022-00473_ophthalmol_ther.pdf (506.4 Ko) Télécharger le fichier
Origin Publisher files allowed on an open archive

Dates and versions

hal-03615616 , version 1 (21-03-2022)

Licence

Identifiers

Cite

Sanjeeb Bhandari, Pierre-Henry Gabrielle, Vuong Nguyen, Vincent Daien, Francesco Viola, et al.. Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry. Ophthalmology and Therapy, 2022, 11 (2), pp.797 - 810. ⟨10.1007/s40123-022-00473-3⟩. ⟨hal-03615616⟩

Collections

INRAE
8 View
15 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More